Advanced Therapies Improve Health-Related Quality of Life in Crohn’s Disease
A systematic review and network meta-analysis concluded that biologics and oral small molecules were effective in improving health-related quality of life (HR-QoL) in moderate-to-severe Crohn’s disease (CD), investigators reported in the American Journal of Gastroenterology.
Focusing on changes in the Inflammatory Bowel Disease Questionnaire (IBDQ) score as the primary outcome, the researchers reviewed 34 randomized controlled trials of approved advanced therapies for CD. “In pairwise meta-analysis, advanced therapies were associated with improvements in IBDQ score (MD 16.07, 95% CI 12.59 – 19.54) after induction,” the authors wrote. “In network meta-analysis, upadacitinib 45mg ranked first for change in IBDQ after induction (MD 23.10, 95% CI 14.41 – 31.78, P-score 0.86).”
Advanced therapies also demonstrated significant improvements in IBDQ score in pairwise meta-analysis (MD 12.72, 95% CI 10.47 – 14.97) in maintenance studies, with infliximab 10mg/kg ranking highest in IBDQ after maintenance (MD 24.91, 95% CI 12.99 – 36.83, P-score 0.90)
“These findings highlight the comparative efficacy of advanced therapies in enhancing HR-QoL in CD," the authors concluded.
Olivera PA, Parks ML, Zubiaurre I et al. Comparative improvement in health-related quality of life with advanced therapies for moderate-to-severe Crohn’s disease: a network meta-analysis. January 29, 2025. Am J Gastroenterol. DOI: 10.14309/ajg.0000000000003333
